Imogen Coe
Director, Coe Lab, Toronto Metropolitan University NSERC Scholar in Residence Professor Researcher, Institute of Biomedical Engineering, Science and Technology (iBEST) Faculty of Science Department of Chemistry and Biology Toronto, Ontario imogen.coe@torontomu.ca
Expert In
Biological processes and pharmaceuticals
COVID-19 anti-viral drugs
COVID-19 cellular transport mechanisms
COVID-19 drug uptake
ENT1 and ENT2 life within cell
Equilibrative Nucleoside Transporters (ENTs)
Equity, diversity and inclusion in STEM
Health and well-being
IBEST
Improved chemotherapies
Justice, equity and society
Membrane transport proteins
Science communication
Sex and gender-based analysis in science and medicine
SLC29 family of ENTs
Bio/Research
Dr. Imogen Coe's research is aimed at obtaining a better understanding of the molecular, cellular and physiological properties of ENTs and their relationships to each other and other nucleoside metabolic (e.g. enzymes) and signalling (e.g. receptors) proteins. Recent studies in ENT1 and ENT2 knoc...
Click to Expand >>
Click to Expand >>
Bio/Research
Dr. Imogen Coe's research is aimed at obtaining a better understanding of the molecular, cellular and physiological properties of ENTs and their relationships to each other and other nucleoside metabolic (e.g. enzymes) and signalling (e.g. receptors) proteins. Recent studies in ENT1 and ENT2 knockout mice and identification of human disorders linked to mutations in ENT3 (a subcellular isoform) suggest that these proteins are important in cellular homeostasis and human health. The most evolutionarily divergent isoform, ENT4 (PMAT), transports both adenosine and organic cations, such as serotonin.
Dr. Coe also serves on the Board of Directors of the Michael Garron Hospital (formerly the TEGH) and the Canadian Mining Innovation Council. She is a member of the Executive Advisory Council for Champions for Change, an initiative of FIRST Canada also serves as an advisor to hErVOLUTION, a non-profit organization working on access to innovative education and employment services for girls and young women in STEM.
Dr. Coe is well known for her promotion and advocacy of equity, diversity and inclusivity (EDI) in science, technology, engineering and math (STEM). She is considered to be a Canadian thought leader in this area and is a highly sought-after speaker and panellist on the topic. In 2016, she was announced as one of WXN’s Top 100 Most Powerful Women in Canada in the Sunlife Financial Trailblazer & Trendsetter category.
Click to Shrink <<
Dr. Coe also serves on the Board of Directors of the Michael Garron Hospital (formerly the TEGH) and the Canadian Mining Innovation Council. She is a member of the Executive Advisory Council for Champions for Change, an initiative of FIRST Canada also serves as an advisor to hErVOLUTION, a non-profit organization working on access to innovative education and employment services for girls and young women in STEM.
Dr. Coe is well known for her promotion and advocacy of equity, diversity and inclusivity (EDI) in science, technology, engineering and math (STEM). She is considered to be a Canadian thought leader in this area and is a highly sought-after speaker and panellist on the topic. In 2016, she was announced as one of WXN’s Top 100 Most Powerful Women in Canada in the Sunlife Financial Trailblazer & Trendsetter category.
Click to Shrink <<